JEN-PIN CHUANG^1,2,3, HSIANG-LIN TSAI^4,5, WEI-CHIH SU^4,6,7, PO-JUNG CHEN^4,6, CHING-WEN HUANG^4,5, TSUNG-KUN CHANG^4,6,7, YEN-CHENG CHEN^4,6, CHING-CHUN LI^4,8, YUNG-SUNG YEH^4,9,10, TZU-CHIEH YIN^4,5,11, JAW-YUAN WANG^{4,5,6,12,13,*}

Oncology Research, Vol.32, No.11, pp. 1723-1732, 2024, DOI:10.32604/or.2024.052098 - 16 October 2024

Abstract Background: The pTNM staging system is widely recognized as the most effective prognostic indicator for cancer. The latest update of this staging system introduced a new pathological staging system (ypTNM) for patients receiving neoadjuvant chemoradiotherapy (NACRT). However, whether the prognostic value of the ypTNM staging system for rectal cancer is similar to that of the pTNM staging system remains unclear. This study was conducted to compare the ypTNM and pTNM staging systems in terms of their prognostic value for patients with nonmetastatic rectal cancer undergoing proctectomy. Material and Methods: This study was conducted at a large teaching… More >

Arjun Pon Avudaiappan¹, Pushan Prabhakar¹, Hariharan Ganapathi², Nathan VanderVeer-Harris³, Jorge Caso^1,3, Rohan Garje¹, Murugesan Manoharan^1,3

Canadian Journal of Urology, Vol.30, No.5, pp. 11686-11691, 2023

Abstract Introduction: Radical cystectomy (RC) is an effective curative treatment option for muscle-invasive bladder cancer (MIBC). However, chemoradiation (CRT) is an evolving bladder preservation protocol alternative to RC. With the increase in life expectancy, it is essential to understand the survival outcomes among octogenarians treated with RC and CRT. In this study, we use the National Cancer Database (NCDB) to compare the survival outcomes between RC and CRT in octogenarians.
Materials and methods: We collected the data of patients treated for bladder cancer between 2004 to 2018 from the NCDB. Our primary analytic cohort included patients with MIBC… More >

Vanita Noronha^*, Kumar Prabhash^*, Amit Joshi^*, Vijay Maruti Patil^*, Sanjay Talole^†, Dipti Nakti^*, Arvind Sahu^*, Srushti Shah^‡, Sarbani Ghosh-Laskar^§, Prachi S. Patil^¶, Shaesta A. Mehta^¶, Nirmala Jambhekar^#, Abhishek Mahajan^**, Nilendu Purandare^††

Oncology Research, Vol.23, No.4, pp. 183-195, 2015, DOI:10.3727/096504016X14537290676865

Abstract There are little data on the efficacy and safety of taxane/platinum with definitive radiotherapy (RT) for esophageal/GEJ cancer. This article is a retrospective analysis of patients who received weekly paclitaxel 50 mg/ m2 and carboplatin AUC 2 with radical definitive RT for locally advanced esophageal/GEJ cancer. Between February 2011 and July 2014, 179 patients were included. The median age was 54 years. Ninety-two percent of patients had squamous histology. Mean RT dose was 58.7 Gy in 32 fractions over 53 days, with mean of six chemotherapy cycles. Fifty-six percent of patients developed ³grade 3 acute… More >

Daniel Zwahlen, Paula N. Fishman, John Honey, Michael Milosevic, Ian Tannock

Canadian Journal of Urology, Vol.14, No.1, pp. 3455-3457, 2007

Abstract This report describes an illustrative case of malignant pheochromocytoma of the urinary bladder in a 28-year old man. A combined-modality treatment plan with partial cystectomy and post-operative radiotherapy and concurrent chemotherapy with single agent cisplatin weekly was performed. Three weeks after completing concurrent chemoradiation the first of four planned cycles of cisplatin 25 mg/m² andetoposide 100 mg/m² was administered daily over 3 days. Although there are no controlled series offering proof of benefit, postoperative concurrent chemoradiation followed by chemotherapy alone are reasonable options for patients with residual disease or at high risk for locoregional relapse. More >